Holen Sie sich die Stockscreener-App
4.71
9.94%
-0.52
Handel nachbörslich:
4.59
-0.12
-2.55%
Schlusskurs vom Vortag:
$5.23
Offen:
$4.97
24-Stunden-Volumen:
49,680
Relative Volume:
0.08
Marktkapitalisierung:
$7.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.28M
KGV:
-0.0498
EPS:
-94.66
Netto-Cashflow:
$-9.80M
1W Leistung:
+6.80%
1M Leistung:
-5.61%
6M Leistung:
+46.36%
1J Leistung:
-64.31%
1-Tages-Spanne:
$4.60
$5.24
1-Wochen-Bereich:
$3.80
$5.30
52-Wochen-Spanne:
$2.098
$23.01
Portage Biotech Inc Stock (PRTG) Company Profile
Firmenname
Portage Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRTG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTG
Portage Biotech Inc
|
4.71 | 7.75M | 0 | -67.28M | -9.80M | -94.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-02 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
Portage Biotech Inc Aktie (PRTG) Neueste Nachrichten
What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News
Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph
Portage Biotech Secures $2.15 Million in Private Financing - TipRanks
Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times
Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq
Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan
Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World
Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company - The Manila Times
Portage Biotech Launches Cyncado Therapeutics to Pioneer Advanced Cancer Immunotherapy Development - StockTitan
(PRTG) Trading Signals - Stock Traders Daily
(PRTG) Trading Advice - Stock Traders Daily
Portage Biotech Inc (PRTG) Recovers 276.55% From Low: Are We There Yet? - Stocks Register
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN
Portage Biotech Inc. Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd - Marketscreener.com
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Portage Biotech soars after initiating proceedings for iOx Therapeutics sale - Mugglehead
What's Going On With Portage Biotech Shares Tuesday?Portage Biotech (NASDAQ:PRTG) - Benzinga
Crude Oil Down Over 1%; US Industrial Production Declines In November - Benzinga
Portage Biotech (PRTG) Stock Soars Amid Strategic Transaction - Stocks Telegraph
Strategic moves ignite these stocks 🧨 - RagingBull
Portage Biotech Shares Double on Letter of Intent to Sell Subsidiary - MarketWatch
Dow Dips Over 200 Points; US Retail Sales Top Estimates - Benzinga
Clinical Trials News Live Feed - StockTitan
Cash-strapped Portage finds hope in sale of lead asset, subsidiary to Immunova - Fierce Biotech
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd - The Manila Times
Portage Biotech Enters Negotiations with Immunova for iOx Acquisition - TipRanks
Portage Biotech enters LOI with Immunova for subsidiary sale - Investing.com
Portage Biotech Inc. Appoints New CEO Amid Leadership Change - TipRanks
Westport-based Portage Biotech faces delisting from Nasdaq - Hartford Business Journal
AI firm Xaira powers up C-suite with pharma vet—Chutes & Ladders - Fierce Biotech
Portage Biotech receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada
Portage Biotech receives noncompliance notification from Nasdaq - TipRanks
Portage Biotech Receives Nasdaq Noncompliance Notice - TipRanks
Portage Biotech receives Nasdaq non-compliance notice - Investing.com
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter - The Manila Times
Full Stock Market News from 2024-12-06 - StockTitan
Portage Biotech Announces Key Leadership Changes - TipRanks
Portage Biotech (NASDAQ:PRTG) Stock Quotes, Forecast and News Summary - Benzinga
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - The Manila Times
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Portage Biotech Reports Reduced Losses and Strategic Plans - TipRanks
Portage Biotech Narrows Q3 Loss by 73% to $1.4M, Pauses Clinical Trial Amid Strategic Review - StockTitan
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 1.51% - MSN
Kronos mulls ‘strategic alternatives’ after axing cancer drug development - MSN
Insiders Who Purchased US$1.24m Of Portage Biotech Stock May Not Have Expected 11% Tumble - Simply Wall St
Portage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With Losses - Yahoo Finance
ARMISTICE CAPITAL, LLC Reduces Stake in Portage Biotech Inc - GuruFocus.com
Portage Biotech Inc (PRTG) Quarterly 10-Q Report - Quartzy
Finanzdaten der Portage Biotech Inc-Aktie (PRTG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):